Palisade Bio Inc (PALI NASDAQ) stock market data APIs
$1.8186
0(0%)
as of May 19, 2026
Try our APIs with
free plan!
Palisade Bio Inc Financial Data Overview
Price chart is built with
Anychart
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Prev. Close
1.8186
Open
1.8251
High
1.858
Low
1.818
52 wk Range
0.53-2.86
Market Cap
315 M
P/E Ratio
15.0833
Shares Outstanding
174 M
EPS
-0.0458
Beta
1.533
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Palisade Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Palisade Bio Inc data using free add-ons & libraries
Get Palisade Bio Inc Fundamental Data
Palisade Bio Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -26 491 250
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-13
- EPS/Forecast: -0.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Palisade Bio Inc News
New
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its cl...
PALISADES ANNOUNCES LOAN FACILITY WITH BANK OF MONTREAL AND CONVERSION OF NOTE INTO COMMON SHARES
VANCOUVER, BC, April 27, 2026 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") announces that it has entered into a loan agreement (the "BMO Loan Facility"), as borrower, ...
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Palisade Bio, Inc. is among the best biotech stocks to buy under $10. TheFly reported on April 8 that Wolfe Research initia...
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities an...
Get Palisade Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
